Locally manufactured versus commercial CAR T therapy for large B-cell lymphoma : a multi-center propensity score-matched analysis

Locally manufactured chimeric antigen receptor T-cell (CAR T) therapy enables rapid manufacturing and a substantially shorter vein-to-vein time. However, its clinical efficacy compared to commercial CAR T products remains unclear. This retrospective study compared outcomes in patients with Large B-...

Descrición completa

Detalles Bibliográficos

Principais autores:	Ronit Marcus, Abraham Avigdor, Uri Greenbaum, Samantha Brown, Shalev Fried, Noa Golan-Accav, Noga Shem-Tov, Ronit Yerushalmi, Ivetta Danylesko, Elad Jacoby, Arnon Nagler, Avichai Shimoni, Orit Itzhaki, Jonathan Esensten, Ori Ben Valid, Annamaria Ballweg, Xavier Deschênes-Simard, Efrat Luttwak, Gunjan Shah, Michael Scordo, Parastoo Dahi, Miguel-Angel Perales, Tsila Zuckerman, Sean M. Devlin, Dana Yehudai-Ofir, Hazim Khatib, Nivin Shibly, Roni Shouval, Ofrat Beyar-Katz
Formato:	Artigo
Idioma:	Inglês
Publicado:	Ferrata Storti Foundation 2025-12-01
Series:	Haematologica
Acceso en liña:	https://haematologica.org/article/view/13066
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!